Match Document Document Title
7183390 Humanized antibodies to gamma-interferon  
The invention provides humanized immunoglobulins that bind to and neutralize γ-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
7183384 Monoclonal antibody 7H11 reactive with human cancer  
Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of...
7179893 Recombinant anti-TNF-α antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7179466 Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7179595 Compositions and methods for generating antigen-binding units  
The present invention provides non-single-chain antigen-binding units that is stabilized by leucine zipper sequences. The experimental design is particularly useful for generating and screening for...
7175847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4  
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
7175996 Methods of optimizing antibody variable region binding affinity  
The present invention relates to compositions and methods of producing higher affinity molecules, and in particular, higher affinity antibodies. Specifically, the invention contemplates methods of...
7177766 Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites  
The invention provides criteria and methods for selecting optimum subsequence(s) from a target gene for targeting by a zinc finger protein. Some of the methods of target site selection seek to...
7172759 Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies  
Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40.
7172758 Endothelialization of vascular surfaces  
Endothelialization of vascular surfaces. According to one aspect, the invention involves a technique for re-endothelializing an artery whose endothelial layer has been damaged by balloon...
7169386 Methods of treating inflammation associated with viral infection with anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7169566 Metalloproteinases  
The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins....
7169903 Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria  
The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and...
7169388 Methods of inhibiting TNFα in patients with cancer  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7169389 Human CD154 binding molecules and treatment methods  
A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid...
7169904 Immunocytokine sequences and uses thereof  
The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified...
7166700 PRO703 Polypeptides  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7166284 Methods of treating joint inflammation with anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7166703 PRO1561 polypeptides  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7166697 V-like domain binding molecules  
The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being...
7164009 Pro9821 polypeptides  
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or...
7160987 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation  
A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind...
7160542 Method of treating psoriasis using human anti-TNF antibodies and fragments  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7160543 Methods of inhibiting TNF-α in patients with Crohn's disease  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7160988 Altering protein functional properties through terminal fusions  
We disclose isolated terminal fusion polypeptides comprising a soybean glycinin or proglycinin polypeptide operably linked to the peptide of SEQ ID NO:12.
7157558 Polypeptide encoded by a polynucleotide overexpresses in tumors  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7157086 Treatment for inflammatory bowel disease with α4-specific antibodies  
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
7157238 Diagnostic and therapeutic use of antibodies against the urokinase receptor  
The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid...
7157085 Method for treating IgE-mediated disorders  
The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which...
7153701 Method for quantitatively detecting antigen  
A method for quantitatively detecting an antigen which comprises (1) a first step of providing an Fab′ antibody having a uniform isoelectric point, said antibody forming an immune complex with an...
7153941 Antibodies that bind PRO4994 polypeptides  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7153508 Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4  
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
7153939 PRO354 antibodies  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7153666 Methods and compositions for determination of glycated proteins  
This invention relates generally to the field of glycated protein detection. In particular, the invention provides chimeric proteins, nucleic acids encoding the chimeric proteins, methods and kits...
7153669 Nucleic acids encoding MK61 receptors  
Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also...
7153661 Artificial antibody polypeptides  
A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also...
7153932 Immunotoxins comprising ribosome-inactivating proteins  
The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding...
7151164 Anti-CD20 antibodies and fusion proteins thereof and methods of use  
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the...
7147851 Humanized immunoglobulin reactive with α4β7 integrin  
The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a...
7148321 Expression technology for proteins containing a hybrid isotype antibody moiety  
Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more...
7148326 Tumor antigen  
Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide...
7148038 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof  
Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung,...
7144991 Streptavidin expressed gene fusions and methods of use thereof  
The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular...
7141653 Human monoclonal antibodies to interleukin-5  
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human...
7141651 Multiple cytokine protein complexes  
The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety...
7138498 Antibodies to MCP-4  
Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods...
7138118 Methods of treating rheumatoid arthritis with anti-TNF antibodies  
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
7138497 Biosynthetic binding proteins for immuno-targeting  
Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic...
7138501 Antibodies that immunospecifically bind BLyS  
The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for...
7138496 Human monoclonal antibodies against human CXCR4  
Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable...